New Data Reveals Tocilizumab Is The First And Only Biologic Drug To Show Superiority Over Current Standard Of Care In Rheumatoid Arthritis

The innovative rheumatoid arthritis drug tocilizumab has shown superiority over the current standard of care, methotrexate (MTX), by achieving a greater reduction of signs and symptoms at 6 months in patients suffering from rheumatoid arthritis(RA). This new data, presented today at The European League Against Rheumatism (EULAR) meeting in Paris, makes tocilizumab the first and only biologic therapy to have achieved superiority over MTX.


Furthermore, nearly three times as many patients treated with the therapy achieved disease remission (34% vs. 12%) as defined by the globally recognised measure DAS28







In the AMBITION study, 70%, 44% and 28% of patients in the tocilizumab (8 mg/kg) monotherapy arm achieved ACR20, ACR50 and ACR70 compared, respectively, with 53%, 34% and 15%, respectively, of patients treated with MTX alone.1 Disease remission (DAS28